Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
Gibbs Cancer Center-Gaffney
mi
from
Gaffney, SC
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
Gibbs Cancer Center-Gaffney
mi
from
Gaffney, SC
Click here to add this to my saved trials
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
Gibbs Cancer Center-Pelham
mi
from
Greer, SC
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
Gibbs Cancer Center-Pelham
mi
from
Greer, SC
Click here to add this to my saved trials
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
MultiCare Auburn Medical Center
mi
from
Auburn, WA
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
MultiCare Auburn Medical Center
mi
from
Auburn, WA
Click here to add this to my saved trials
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
MultiCare Gig Harbor Medical Park
mi
from
Gig Harbor, WA
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
MultiCare Gig Harbor Medical Park
mi
from
Gig Harbor, WA
Click here to add this to my saved trials
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
MultiCare Good Samaritan Hospital
mi
from
Puyallup, WA
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
MultiCare Good Samaritan Hospital
mi
from
Puyallup, WA
Click here to add this to my saved trials
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated:  8/23/2017
Billings Clinic-Cody
mi
from
Cody, WY
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Status: Enrolling
Updated: 8/23/2017
Billings Clinic-Cody
mi
from
Cody, WY
Click here to add this to my saved trials
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated:  8/31/2017
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated: 8/31/2017
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly
The Effect of Consumption of 2 Eggs or 4 oz of Egg Substitute Daily for 6 Months on Cognitive Function in Older Adults.
Status: Enrolling
Updated:  8/31/2017
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
mi
from
Boston, MA
The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly
The Effect of Consumption of 2 Eggs or 4 oz of Egg Substitute Daily for 6 Months on Cognitive Function in Older Adults.
Status: Enrolling
Updated: 8/31/2017
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
mi
from
Boston, MA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Collaborative Neuroscience Network, LLC (Investigator Site File Location)
mi
from
Garden Grove, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Collaborative Neuroscience Network, LLC (Investigator Site File Location)
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Excell Research, Inc.
mi
from
Oceanside, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
NRC Research Institute
mi
from
Orange, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
mi
from
San Diego, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Alexian Brothers Centers for Psychiatric Research
mi
from
Hoffman Estates, IL
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Alexian Brothers Centers for Psychiatric Research
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Chinmay K. Patel, D.O.
mi
from
Hoffman Estates, IL
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Chinmay K. Patel, D.O.
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
CBH Health, LLC
mi
from
Gaithersburg, MD
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
CBH Health, LLC
mi
from
Gaithersburg, MD
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Hassman Research Institute
mi
from
Berlin, NJ
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Hassman Research Institute
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
CRI Worldwide
mi
from
Marlton, NJ
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
CRI Worldwide
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Pillar Clinical Research, LLC
mi
from
Dallas, TX
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated:  9/5/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Status: Enrolling
Updated: 9/5/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Memantine and Cognitive Dysfunction in Bipolar Disorder
Memantine and Cognitive Dysfunction in Bipolar Disorder
Status: Enrolling
Updated:  9/7/2017
Cedars Sinai Department of Psychiatry
mi
from
Los Angeles, CA
Memantine and Cognitive Dysfunction in Bipolar Disorder
Memantine and Cognitive Dysfunction in Bipolar Disorder
Status: Enrolling
Updated: 9/7/2017
Cedars Sinai Department of Psychiatry
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Memantine and Cognitive Dysfunction in Bipolar Disorder
Memantine and Cognitive Dysfunction in Bipolar Disorder
Status: Enrolling
Updated:  9/7/2017
Asher Depression Center, Northwestern University
mi
from
Chicago, IL
Memantine and Cognitive Dysfunction in Bipolar Disorder
Memantine and Cognitive Dysfunction in Bipolar Disorder
Status: Enrolling
Updated: 9/7/2017
Asher Depression Center, Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Memantine and Cognitive Dysfunction in Bipolar Disorder
Memantine and Cognitive Dysfunction in Bipolar Disorder
Status: Enrolling
Updated:  9/7/2017
Massachusetts General Hospital
mi
from
Boston, MA
Memantine and Cognitive Dysfunction in Bipolar Disorder
Memantine and Cognitive Dysfunction in Bipolar Disorder
Status: Enrolling
Updated: 9/7/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Fish Oil T Cell Function
Nutritional Intervention to Test Effect on Healthy Human T Cell Function
Status: Enrolling
Updated:  9/7/2017
Texas A&M University-CTRAL
mi
from
College Station, TX
Fish Oil T Cell Function
Nutritional Intervention to Test Effect on Healthy Human T Cell Function
Status: Enrolling
Updated: 9/7/2017
Texas A&M University-CTRAL
mi
from
College Station, TX
Click here to add this to my saved trials
Donepezil HCl & Cognitive Deficits in Autism
Donepezil HCl: Treating Cognitive Deficits in Autism
Status: Enrolling
Updated:  9/7/2017
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Donepezil HCl & Cognitive Deficits in Autism
Donepezil HCl: Treating Cognitive Deficits in Autism
Status: Enrolling
Updated: 9/7/2017
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)
From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services
Status: Enrolling
Updated:  9/14/2017
Univ of Washington
mi
from
Seattle, WA
Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)
From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services
Status: Enrolling
Updated: 9/14/2017
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
University of California Davis Cancer Center
mi
from
Sacramento, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Baptist-South Miami Regional Cancer Program
mi
from
Miami, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Baptist-South Miami Regional Cancer Program
mi
from
Miami, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Florida Cancer Center - Palatka
mi
from
Palatka, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Florida Cancer Center - Palatka
mi
from
Palatka, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Piedmont Hospital
mi
from
Atlanta, GA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Rush University Medical Center
mi
from
Chicago, IL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
OSF St. Francis Medical Center
mi
from
Peoria, IL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Center for Cancer Care at Goshen General Hospital
mi
from
Goshen, IN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Center for Cancer Care at Goshen General Hospital
mi
from
Goshen, IN
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Methodist Cancer Center at Methodist Hospital
mi
from
Indianapolis, IN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Methodist Cancer Center at Methodist Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials